PFE-N
PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.
PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.
Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.
Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.
Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.
ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.
ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 6
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 10
Total Signals / Votes : 17
Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N
In the last year, 17 stock analysts published opinions about PFE-N. 6 analysts recommended to BUY the stock. 10 analysts recommended to SELL the stock. The latest stock analyst recommendation is SELL. Read the latest stock experts' ratings for Pfizer Inc.
Pfizer Inc was recommended as a Top Pick by Jamie Murray on 2020-11-23. Read the latest stock experts ratings for Pfizer Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
17 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.
On 2020-12-02, Pfizer Inc (PFE-N) stock closed at a price of $40.8.
